Rani Therapeutics (US:RANI) Zhi Tong Cai Jing·2025-10-17 15:52Core Viewpoint - Rani Therapeutics' stock surged over 265% following a partnership announcement with Chugai Pharmaceutical, reaching a new high of $1.76 per share [1] Group 1: Partnership Details - The collaboration with Chugai Pharmaceutical is valued at up to $1.085 billion, including an upfront payment of $10 million [1] - Rani Therapeutics is eligible for up to $75 million in technology transfer and development milestone payments, $100 million in sales milestone payments, and single-digit royalties [1] - Chugai has the option to expand the partnership to five additional drug targets [1] Group 2: Company Overview - Rani Therapeutics specializes in oral delivery technology for biopharmaceuticals, with its core platform, RaniPill, focusing on oral antibodies and rare disease drug development [1] - The partnership aims to apply Rani's technology to Chugai's rare disease antibody projects, validating the application value of Rani's technology [1]